Healios K.K (OTCPK:HLOS.F) - Stock Price, News & Analysis

HLOS.F Stock Overview

Engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. More details

HLOS.F fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 40.38% per year

Analysts in good agreement that stock price will rise by 73.5%

Risk Analysis

Shares are highly illiquid

Does not have meaningful revenue (¥521M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Healios K.K. Competitors

CervoMed

NasdaqCM:CRVO

US$79.1m

Assembly Biosciences

NasdaqGS:ASMB

US$93.6m

Compugen

NasdaqCM:CGEN

US$129.8m

Adaptimmune Therapeutics

NasdaqGS:ADAP

US$162.8m

Price History & Performance

Summary of all time highs, changes and price drops for Healios K.K
Historical stock prices
Current Share Price	JP¥1.20
52 Week High	JP¥1.73
52 Week Low	JP¥0.93
Beta	0.93
11 Month Change	-20.00%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-93.51%

Recent updates

Shareholder Returns

	HLOS.F	US Biotechs	US Market
7D	-20.0%	2.4%	2.2%
1Y	n/a	16.2%	31.7%

Return vs Industry: Insufficient data to determine how HLOS.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how HLOS.F performed against the US Market.

Price Volatility

Is HLOS.F's price volatile compared to industry and market?
HLOS.F volatility
HLOS.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: HLOS.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine HLOS.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	64	Hardy Kagimoto	www.healios.co.jp

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013.

Healios K.K. Fundamentals Summary

How do Healios K.K's earnings and revenue compare to its market cap?
HLOS.F fundamental statistics
Market cap	US$114.09m
Earnings (TTM)	-US$34.80m
Revenue (TTM)	US$3.36m

33.9x

P/S Ratio

-3.3x

P/E Ratio

Is HLOS.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLOS.F income statement (TTM)
Revenue	JP¥521.00m
Cost of Revenue	JP¥68.00m
Gross Profit	JP¥453.00m
Other Expenses	JP¥5.84b
Earnings	-JP¥5.39b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-59.79
Gross Margin	86.95%
Net Profit Margin	-1,034.36%
Debt/Equity Ratio	185.1%

How did HLOS.F perform over the long term?

See historical performance and comparison